A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

• Status: RECRUITING
• Trial end date: 2029-08-27

Summary

A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Memorial Sloan Kettering Cancer Center (MSK); PMV Pharmaceuticals, Inc
• Treatments: Azacitidine